Industrial conglomerate 3M Company is partnering with the Massachusetts Institute of Technology to develop a cheaper, quicker COVID-19 test.
Right now, test results can take anywhere from a few hours to a week. Quest Diagnostics, for instance, said the average turnaround time at its labs is currently seven days.
3M's new test would function more like a pregnancy strip, a rapid paper-based test that could be mass-produced and quickly distributed at the point of care.
"In terms of patient experience, what we're looking to do is create that low-cost, highly-accurate, simple-to-use test that would be accessible to a lot of people," Dr. John Banovetz, chief technology officer for 3M, told Cheddar.
The antigen-based test, which looks at proteins on the virus, would offer a "preliminary view" of a patient's coronavirus status — though ideally, patients would follow up with a doctor, he added.
"Our goal would be a point-of-care test, so maybe it's taken in a doctor's office. Maybe you pick it up at the pharmacy," Banovetz said.
The goal is to start producing tests by the end of summer or early fall. Once manufacturing is rolling, 3M could produce millions of tests per day, according to the company.
As cases surge across the country and many anticipate a second wave in states where the infection rate has dropped off, calls for more testing are growing.
More than 41 million tests have been reported to the CDC, with a 9 percent positivity rate, but the U.S. continues to lag behind other countries by some measures.
In the meantime, the Trump administration is relying on the private sector to meet the demand for tests, putting pressure on companies such as 3M to come up with a solution.
"We're going as quick as we can right now," he said. "Our focus is trying to get that accuracy up and in a way that we know that we can mass-produce it. That's really where 3M can help contribute to this, our ability to be able to commercialize and bring to market new ideas and innovations."
Dr. Farhan Bhatti, a family physician and Michigan State lead for the Committee to Protect Health Care, joined Cheddar to discuss the newly discovered and highly transmissible omicron variant of COVID-19. Bhatti said it is too early to draw any conclusions about the new variant but there is concern that it could eventually mutate and develop a resistance to vaccines. "Time will tell, but for now, it looks like, still, the best thing that we can do to try to limit the spread of this disease is make sure everybody gets a vaccine and make sure everybody avoids large gatherings indoors and wears masks during the wintertime especially," he said.
Jill and Carlo cover the latest developments with the Omicron variant that are spooking markets once again. Twitter's @Jack is leaving, SCOTUS takes up abortion rights and the world has a brand new republic.
A CDC panel unanimously endorsed Moderna and Pfizer Covid-19 vaccine boosters for all U.S. adults. This comes after the FDA gave its own authorization for everyone 18 and older, scrapping previous eligibility factors like age and underlying conditions. Dr. Shereef Elnahal, President and CEO of University Hospital and former New Jersey Health Commissioner, joined Cheddar News to break down the development.
The Biden Administration is set to buy 10 million courses of Pfizer's Covid pill if it gains emergency use authorization from the FDA. With this purchase, the U.S. will receive more than 13 million courses of antiviral pills aimed at treating Covid and reducing severe illness and death. Pfizer's pill has been shown to reduce risk of hospitalization and death by 89 percent, proving it could be a key tool in the fight against the pandemic. Dr. Soumi Eachempati, Co-Founder, CEO & CMO of Cleared4, joined Cheddar News to discuss.
Dr. David Dodson, Infectious Disease Specialist at Carden & Dodson MD, joined Wake Up With Cheddar to break down what we know so far about the Omicron Covid-19 variant, and why you shouldn't wait for an Omicron-specific shot to get vaccinated.
Friday saw big sell offs, with the Dow Jones posting its worst day since October 2020, falling 905 points, with the Nasdaq and S&P 500 each tumbling more than two percent as well. Much of that due to investor concerns over the new Covid-19 'Omicron' variant first detected in South Africa. Craig Erlam, senior market analyst at Oanda explains what investors should expect this week.
The ocean is an important topic when it comes to the climate. It plays a vital role in shaping our environment, with rising sea levels causing a 35% increase in natural disasters around the world, affecting 1.7 billion people. Dr. Sylvia Earle has been called perhaps the greatest advocate our oceans have ever had, with Time magazine dubbing her its first 'hero of the planet' and the Library of Congress naming her a living legend. She is also the founder of Mission Blue, an organization that inspires action to explore and protect the ocean. Dr. Earle joined Cheddar Climate for more on the importance of caring for the ocean and its impact on climate change.
Scientists are racing to understand the Omicron variant of covid-19 and find out just how dangerous it really is. Omicron, dubbed a variant of concern by the WHO, was first detected in South Africa last week and has already spread to multiple countries, including the UK, Canada, Australia and more. Dr. Jonathan Javitt, CEO of Nrx and adjunct professor at Johns Hopkins School of Medicine, joined Cheddar to discuss what we know and don't know about this new variant.
The House has officially passed the $1.75 trillion social policy and climate big. This new bill is expected to bring some huge investments into working towards fighting climate change. U.S. President of We Don't Have Time, Sweta Chakraborty, joined Cheddar to discuss more.
